Archive
Here you can find the archive of all Press Releases prior to 2018
Filter by date:
Showing 647 press releases before 2018
-
AstraZeneca Terminates License Agreement with MAP Pharmaceuticals Regarding Unit Dose Budesonide
-
AstraZeneca to Advance AZD3480 in ADHD
-
IRESSA (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in Europe
-
AstraZeneca Development Partner, Pozen, Inc., Submits New Drug Application for PN400
AstraZeneca Development Partner, Pozen, Inc., Submits New Drug Application for PN400
-
ONGLYZA (saxagliptin) Receives Positive Opinion in Europe for the Treatment of Type 2 Diabetes
-
Favourable Vote from FDA Advisory Committee on Seroquel Paediatric Supplemental New Drug Applications
-
AstraZeneca and Abbott Extend Relationship to Include Co-Promotion of Trilipix
-
AstraZeneca and Abbott Submit New Drug Application to the FDA for the Approval of CERTRIAD for the Treatment of Mixed Dyslipidemia
-
AstraZeneca and Merck & Co., Inc. Form Pioneering Collaboration to Investigate Novel Combination Anticancer Regimen
-
AstraZeneca Regulatory Update on Seroquel XR for the Treatment of Major Depressive Disorder
Latest articles and press releases
All of our latest press releases and articles are available to explore
Contact us
Gonzalo Viña
Head of Global Media Relations
+44 203 749 5916
Rob Skelding
Director Global Media Relations (Oncology)
+44 203 749 5821
Rebecca Einhorn
Director Global Media Relations (Oncology)
+1 301 398 1802
Matthew Kent
Director Global Media Relations (BioPharmaceuticals)
+44 203 749 5906
Angela Fiorin
Director Global Media Relations (BioPharmaceuticals)
+44 122 334 4690
Jennifer Hursit
Manager Global Media Relations
+44 203 749 5762
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
